Clinical trial NCT04930549: Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
Official title: Impact of Dapagliflozin on Vascular Function in Chronic Kidney Disease Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Renal Insufficiency, Chronic
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2021-06-18
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to determine whether dapaglfiflozin 12-week administration is associated with a beneficial impact on the vasculature of patients with chronic kidney disease.

Detailed description: A prospective, randomized, double-blind studies evaluating the impact of once-daily dapagliflozin 10 mg versus placebo for 12 weeks on endothelial function, as primary endpoint, will be conducted in 56 patients with chronic kidney disease (eGFR ≥25 and ≤60 mL/min/1.73m2 by CKD-EPI) and without diabetes (fasting glycemia≥1.26 mg/dL, oral hypoglycemic agents or insulin) on top of standard treatment (n=27 per group). Indexes of arterial stiffness, cardiovascular coupling, cardiac function and plasma concentrations of endothelial, inflammatory and oxidative stress biomarkers will be assessed as secondary endpoints. Patients will be recruited in the Departments of Cardiology and Nephrology of Rouen University Hospital. The study will include an inclusion visit (V1), 2 exploration visits performed before (V2) and 12 weeks (V3) after treatment initiation, and 1 output study (V4).

Eligibility criteria: Inclusion Criteria:

* Chronic kidney disease (eGFR ≥25 and ≤60 mL/min/1.73m² by CKD-EPI)
* Age ≥ 18 years
* Receiving a stable dose of an ACE inhibitor or ARB for at least 12 weeks before screening or patients who were documented to be intolerant to ACE inhibitors or ARBs

Exclusion Criteria:

* Type 1 and type 2 diabetes (fasting glycemia≥126 mg/dL or use of oral hypoglycemic agents or insulin)
* Recessive or autosomal dominant polycystic kidney disease
* Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
* Lupus nephritis
* Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
* History of organ transplantation
* Body weight \> 35 kg/m²
* Receiving therapy with a sodium glucose co-transporter 2 (SGLT2) inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
* Patients with NYHA class IV congestive heart failure at the time of enrolment
* Myocardial infarction, unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks prior to enrolment
* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or is planned to undergo any of these procedures after randomization
* Active malignancy requiring treatment at the time of enrolment or is planned to undergo any treatment after randomization
* Severe hepatic impairment (Child-Pugh class C)
* History of frequent genital mycotic infections (\>2)
* Current pregnancy OR women of child-bearing potential (ie, those who are not chemically or surgically sterilized or who are not post-menopausal) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator OR women who have a positive pregnancy test at enrolment or exploration visits OR women who are breast-feeding
* Contraindications to use glyceryl trinitrate (in particular allergy to nitrates or concomitant use of vasodilators)
* Participation in another clinical study with an investigational product during the last month prior to enrolment
* Inability of the patient, in the opinion of the investigator, to understand and/or comply with procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.

Primary outcomes:
measure: Change from baseline of brachial artery endothelial function using echography
timeFrame: 12 weeks
Secondary outcomes:
measure: Change from baseline of arterial stiffness using applanation tonometry
timeFrame: 12 weeks
measure: Change from baseline of carotid artery geometry using echography (1)
timeFrame: 12 weeks
measure: Change from baseline of carotid artery geometry using echography (2)
timeFrame: 12 weeks
measure: Change from baseline of cardiac function by impedance cardiography (1)
timeFrame: 12 weeks
measure: Change from baseline of cardiac function by impedance cardiography (2)
timeFrame: 12 weeks
measure: Change from baseline of cardiac function by impedance cardiography (3)
timeFrame: 12 weeks
measure: Change from baseline of cardiac function by impedance cardiography (4)
timeFrame: 12 weeks
measure: Change from baseline of cardiac function by impedance cardiography (5)
timeFrame: 12 weeks
measure: Change from baseline of cardiac function by impedance cardiography (6)
timeFrame: 12 weeks
measure: Change from baseline of epoxyeicosatrienoic acid bioavailability
timeFrame: 12 weeks
measure: Change from baseline of plasma NO bioavailability
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Bois-Guillaume
country: France
facility: Department of Nephrology
city: Rouen
country: France
facility: Department of Pharmacology
Study officials:
affiliation: University Hospital, Rouen
name: Dominique Guerrot, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Rouen
name: Jeremy Bellien, PharmD, PhD
role: STUDY_DIRECTOR
References: